Guercio Gerson D, Panizzutti Rogerio
Instituto de Ciencias Biomedicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland.
Front Psychiatry. 2018 Feb 5;9:14. doi: 10.3389/fpsyt.2018.00014. eCollection 2018.
After 25 years of its discovery in the rat brain, d-serine is a recognized modulator of synaptic plasticity and cognitive processes through its actions on the NMDA-glutamate receptor. Importantly, cognitive impairment is a core feature of conditions, such as schizophrenia, Alzheimer's disease, depression, and aging, and is associated to disturbances in NMDA-glutamate receptors. The d-serine pathway has been associated with cognitive deficits and these conditions, and, for this reason, d-serine signaling is subject of intense research to probe its role in aiding diagnosis and therapy. Nevertheless, this has not resulted in new therapies being incorporated into clinical practice. Therefore, in this review we will address many questions that need to be solved by future studies, regarding d-serine pharmacokinetics, possible side effects, other strategies to modulate its levels, and combination with other therapies to increase its efficacy.
在大鼠脑中发现d-丝氨酸25年后,它已被公认为是一种通过作用于NMDA-谷氨酸受体来调节突触可塑性和认知过程的调节剂。重要的是,认知障碍是精神分裂症、阿尔茨海默病、抑郁症和衰老等病症的核心特征,并且与NMDA-谷氨酸受体的紊乱有关。d-丝氨酸途径已与认知缺陷及这些病症相关联,因此,d-丝氨酸信号传导成为深入研究的对象,以探究其在辅助诊断和治疗中的作用。然而,这尚未导致新的疗法被纳入临床实践。因此,在本综述中,我们将探讨许多未来研究需要解决的问题,涉及d-丝氨酸的药代动力学、可能的副作用、调节其水平的其他策略以及与其他疗法联合以提高其疗效。